Pharmacogenomics of Lipid-Lowering Therapies in Obese Individuals with Dyslipidemia

Kato Jumba K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Dyslipidemia is a key contributor to cardiovascular diseases, especially in obese individuals, where lipid metabolism is frequently impaired. Lipid-lowering therapies, such as statins, fibrates, and PCSK9 inhibitors, are commonly prescribed to manage dyslipidemia, but their efficacy and adverse effect profiles vary significantly across individuals. Pharmacogenomics, the study of how genetic variations influence drug response, has emerged as a powerful tool in predicting these inter-individual differences and optimizing treatment regimens. In obese individuals, genetic polymorphisms in genes involved in lipid metabolism, such as SLCO1B1, CYP3A4, APOE, and LDLR, have been linked to variable responses to lipid-lowering drugs. This review explores the impact of pharmacogenomics on lipid-lowering therapies in obese individuals with dyslipidemia, emphasizing the potential of personalized medicine in improving therapeutic outcomes. By understanding genetic influences on drug efficacy and safety, clinicians can tailor treatments to individual patients, thereby reducing adverse effects and improving lipid control. We also highlight current challenges in translating pharmacogenomic findings into clinical practice and discuss the future directions of this emerging field.

Keywords: Pharmacogenomics, Lipid-Lowering Therapies, Dyslipidemia, Obesity, Statins, Fibrates, PCSK9 Inhibitors

CITE AS: Kato Jumba K. (2024). Pharmacogenomics of Lipid-Lowering Therapies in Obese Individuals with Dyslipidemia. IAA Journal of Applied Sciences 12(1):21-24. https://doi.org/10.59298/IAAJAS/2024/121.21240